US2002187955A1PendingUtilityA1

Method of inducing angiogenesis in nonischemic skeletal muscle

35
Assignee: ISTITUTO DERMOPATICO DELL IMMAPriority: May 27, 1999Filed: Jun 20, 2002Published: Dec 12, 2002
Est. expiryMay 27, 2019(expired)· nominal 20-yr term from priority
Inventors:Maurizio Capogrossi
C07K 14/52A61K 48/00A61K 51/1255C12N 2799/022
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method for attenuating or treating pain in nonischemic skeletal muscle, e.g., by inducing angiogenesis in a nonischemic skeletal muscle, by administration of a pharmaceutical composition comprising a DNA encoding an angiogenic peptide, such that the blood flow to the nonischemic skeletal muscle is enhanced and pain in the nonischemic skeletal muscle is attenuated. A method of treating a symptom associated with risk of ischemic damage in nonischemic skeletal muscle also is provided.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for attenuating pain associated with risk of ischemic damage in non-ischemic skeletal muscle, wherein the method comprises administering to a nonischemic skeletal muscle a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier and (b) a DNA encoding an angiogenic peptide, such that blood flow to the nonischemic skeletal muscle is enhanced and pain in the nonischemic skeletal muscle is attenuated.  
     
     
         2 . The method of  claim 1 , wherein pain is associated with intermittent claudication.  
     
     
         3 . The method of  claim 1 , wherein angiogenesis is induced in the nonischemic skeletal muscle.  
     
     
         4 . The method of  claim 1 , wherein the angiogenic peptide is a vascular endothelial growth factor (VEGF).  
     
     
         5 . The method of  claim 1 , wherein the DNA encoding an angiogenic peptide is in a viral vector.  
     
     
         6 . The method of  claim 5 , wherein the viral vector is an adenoviral vector.  
     
     
         7 . The method of  claim 6 , wherein the adenoviral vector is deficient in at least one essential gene function of the E1 region of the adenoviral genome.  
     
     
         8 . The method of  claim 1 , wherein the skeletal muscle comprises a portion of a human limb.  
     
     
         9 . A method of treating a symptom associated with risk of ischemic damage in nonischemic skeletal muscle, wherein the method comprises administering to a nonischemic skeletal muscle a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier and (b) a DNA encoding an angiogenic peptide, such that blood flow to the nonischemic skeletal muscle is enhanced and the symptom associated with risk of ischemic damage is treated.  
     
     
         10 . The method of  claim 9 , wherein the symptom associated with risk of ischemic damage is pain.  
     
     
         11 . The method of  claim 10 , wherein the pain is associated with intermittent claudication.  
     
     
         12 . The method of  claim 9 , wherein angiogenesis is induced in the nonischemic skeletal muscle.  
     
     
         13 . The method of  claim 9 , wherein the angiogenic peptide is a vascular endothelial growth factor (VEGF).  
     
     
         14 . The method of  claim 9 , wherein the DNA encoding an angiogenic peptide is in a viral vector.  
     
     
         15 . The method of  claim 14 , wherein the viral vector is an adenoviral vector.  
     
     
         16 . The method of  claim 15 , wherein the adenoviral vector is deficient in at least one essential gene function of the E1 region of the adenoviral genome.  
     
     
         17 . The method of  claim 9 , wherein the skeletal muscle comprises a portion of a human limb.  
     
     
         18 . A method for treating pain upon movement, wherein the method comprises administering to a nonischemic skeletal muscle a pharmaceutical composition comprising (a) a pharmaceutically acceptable carrier and (b) a DNA encoding an angiogenic peptide, such that blood flow to the nonischemic skeletal muscle is enhanced and pain in the nonischemic skeletal muscle upon movement is attenuated.  
     
     
         19 . The method of  claim 18 , wherein angiogenesis is induced in the nonischemic skeletal muscle.  
     
     
         20 . The method of  claim 18 , wherein the angiogenic peptide is a vascular endothelial growth factor (VEGF).  
     
     
         21 . The method of  claim 18 , wherein the DNA encoding an angiogenic peptide is in a viral vector.  
     
     
         22 . The method of  claim 21 , wherein the viral vector is an adenoviral vector.  
     
     
         23 . The method of  claim 22 , wherein the adenoviral vector is deficient in at least one essential gene function of the E1 region of the adenoviral genome.  
     
     
         24 . The method of  claim 18 , wherein the skeletal muscle comprises a portion of a human limb.

Join the waitlist — get patent alerts

Track US2002187955A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.